Literature DB >> 12902423

Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.

Leo J Hofland1, Steven W J Lamberts, P Martin van Hagen, Jean-Claude Reubi, James Schaeffer, Marlijn Waaijers, Peter M van Koetsveld, Ananth Srinivasan, Eric P Krenning, Wout A P Breeman.   

Abstract

UNLABELLED: Human somatostatin (SS) receptor (sst)-positive tumors can be visualized by gamma camera scintigraphy after the injection of [(111)In-diethylenetriaminepentaacetic acid (DTPA)-D-Phe(1)] octreotide. Uptake of [(111)In-DTPA-D-Phe(1)]octreotide is dependent on sst-mediated internalization of the radioligand by the tumor cells. Human sst-positive tumors frequently express multiple sst subtypes. In vitro studies have demonstrated that the 5 sst subtypes (sst(1-5)) differentially internalize sst-bound ligand. The present study was performed to evaluate the role of sst(2) in vivo in determining the uptake of [(111)In-DTPA-D-Phe(1)]octreotide, as well as of the more "universal" ligand [(111)In-DTPA]SS-14, by sst-positive organs expressing multiple sst subtypes.
METHODS: Wild-type and sst(2) knockout mice (n = 4 per treatment group) were injected intravenously with 1 MBq (0.1 micro g) [(111)In-DTPA-D-Phe(1)]octreotide or [(111)In-DTPA]SS-14. After 24 h, the animals were sacrificed and radioactivity in the organs under investigation was determined. In addition, the sst subtype messenger RNA (mRNA) expression pattern in these organs was determined by reverse transcriptase polymerase chain reaction (RT-PCR) analysis.
RESULTS: RT-PCR analysis demonstrated the presence of all 5 sst subtype mRNAs in the adrenals and pituitary of wild-type mice but no sst(2) in the knockout mice. The thymus expressed mRNA for sst(2) and sst(4) mRNA in wild-type mice, whereas no sst(2) was detected in knockout mice. In wild-type mice, the in vivo uptake values (in percentage injected dose per gram of tissue) of [(111)In-DTPA-D-Phe(1)]octreotide for the pituitary, adrenals, pancreas, and thymus amounted to 1.2 +/- 0.2, 0.26 +/- 0.03, 0.18 +/- 0.03, and 0.30 +/- 0.05, respectively, in wild-type mice. Compared with wild-type mice, sst(2) knockout mice had dramatically lower uptake values in these organs-lower by 97%, 83%, 96%, and 94%, respectively (P < 0.01 vs. wild type). Comparable differences in the uptake of radioactivity between wild-type and knockout mice were found using [(111)In-DTPA]SS-14 as the radiotracer. Interestingly, in some organs expressing sst(2) mRNA (liver, muscle, and peripheral blood mononuclear cells), no specific binding of [(111)In-DTPA-D-Phe(1)]octreotide or [(111)In-DTPA]SS-14 to sst in vivo was found, suggesting that the sst(2) protein expression level was very low in these tissues.
CONCLUSION: The uptake of [(111)In-DTPA-D-Phe(1)]octreotide and [(111)In-DTPA]SS-14 in sst-positive organs is determined predominantly by sst(2).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902423

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  14 in total

1.  Exploring new frontiers in molecular imaging: Emergence of Ga PET/CT.

Authors:  Eik Hock Tan; Soon Whatt Goh
Journal:  World J Radiol       Date:  2010-02-28

Review 2.  Somatostatin receptor scintigraphy in thoracic diseases.

Authors:  P Ameri; F Gatto; M Arvigo; G Villa; E Resmini; F Minuto; G Murialdo; D Ferone
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

3.  Copper-64 Radiopharmaceuticals for Oncologic Imaging.

Authors:  Jason P Holland; Riccardo Ferdani; Carolyn J Anderson; Jason S Lewis
Journal:  PET Clin       Date:  2009-01

4.  Diagnostic accuracy of (68)Ga-DOTANOC PET/CT imaging in pheochromocytoma.

Authors:  Punit Sharma; Varun Singh Dhull; Saurabh Arora; Poonam Gupta; Rajeev Kumar; Prashant Durgapal; Arun Malhotra; Sunil Chumber; Ariachery C Ammini; Rakesh Kumar; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-25       Impact factor: 9.236

Review 5.  The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.

Authors:  Michael Michael; Rocio Garcia-Carbonero; Matthias M Weber; Catherine Lombard-Bohas; Christos Toumpanakis; Rodney J Hicks
Journal:  Oncologist       Date:  2017-02-20

6.  Localisation and mechanism of renal retention of radiolabelled somatostatin analogues.

Authors:  Marleen Melis; Eric P Krenning; Bert F Bernard; Raffaella Barone; Theo J Visser; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-24       Impact factor: 9.236

7.  Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor.

Authors:  W Barry Edwards; Baogang Xu; Walter Akers; Philip P Cheney; Kexian Liang; Buck E Rogers; Carolyn J Anderson; Samuel Achilefu
Journal:  Bioconjug Chem       Date:  2007-11-20       Impact factor: 4.774

Review 8.  Somatostatin-dopamine ligands in the treatment of pituitary adenomas.

Authors:  Alexandru Saveanu; Philippe Jaquet
Journal:  Rev Endocr Metab Disord       Date:  2008-07-24       Impact factor: 6.514

9.  [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study.

Authors:  Aikaterini Tatsi; Theodosia Maina; Renzo Cescato; Beatrice Waser; Eric P Krenning; Marion de Jong; Paul Cordopatis; Jean Claude Reubi; Berthold A Nock
Journal:  EJNMMI Res       Date:  2012-06-09       Impact factor: 3.138

10.  Effects of therapy with [177Lu-DOTA 0,Tyr 3]octreotate on endocrine function.

Authors:  Jaap J M Teunissen; Eric P Krenning; Frank H de Jong; Yolanda B de Rijke; Richard A Feelders; Maarten O van Aken; Wouter W de Herder; Dik J Kwekkeboom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-27       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.